Imperial College London
Portrait Picture

Professor Hashim Ahmed

Faculty of Medicine, Department of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Marsden:2022:10.1371/journal.pone.0259672,
author = {Marsden, T and McCartan, N and Brown, L and Rodriguez-Justo, M and Syer, T and Brembilla, G and Van, Hemelrijck M and Coolen, T and Attard, G and Punwani, S and Moore, CM and Ahmed, HU and Emberton, M and ReIMAGINE, Study Group},
doi = {10.1371/journal.pone.0259672},
journal = {PLoS One},
title = {The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses},
url = {http://dx.doi.org/10.1371/journal.pone.0259672},
volume = {17},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: The ReIMAGINE Consortium was conceived to develop risk-stratification models that might incorporate the full range of novel prostate cancer (PCa) diagnostics (both commercial and academic). METHODS: ReIMAGINE Risk is an ethics approved (19/LO/1128) multicentre, prospective, observational cohort study which will recruit 1000 treatment-naive men undergoing a multi-parametric MRI (mpMRI) due to an elevated PSA (≤20ng/ml) or abnormal prostate examination who subsequently had a suspicious mpMRI (score≥3, stage ≤T3bN0M0). Primary outcomes include the detection of ≥Gleason 7 PCa at baseline and time to clinical progression, metastasis and death. Baseline blood, urine, and biopsy cores for fresh prostate tissue samples (2 targeted and 1 non-targeted) will be biobanked for future analysis. High-resolution scanning of pathology whole-slide imaging and MRI-DICOM images will be collected. Consortium partners will be granted access to data and biobanks to develop and validate biomarkers using correlation to mpMRI, biopsy-based disease status and long-term clinical outcomes. RESULTS: Recruitment began in September 2019(n = 533). A first site opened in September 2019 (n = 296), a second in November 2019 (n = 210) and a third in December 2020 (n = 27). Acceptance to the study has been 65% and a mean of 36.5ml(SD+/-10.0), 12.9ml(SD+/-3.7) and 2.8ml(SD+/-0.7) urine, plasma and serum donated for research, respectively. There are currently 4 academic and 15 commercial partners spanning imaging (~9 radiomics, artificial intelligence/machine learning), fluidic (~3 blood-based and ~2urine-based) and tissue-based (~1) biomarkers. CONCLUSION: The consortium will develop, or adjust, risk models for PCa, and provide a platform for evaluating the role of novel diagnostics in the era of pre-biopsy MRI and targeted biopsy.
AU  - Marsden,T
AU  - McCartan,N
AU  - Brown,L
AU  - Rodriguez-Justo,M
AU  - Syer,T
AU  - Brembilla,G
AU  - Van,Hemelrijck M
AU  - Coolen,T
AU  - Attard,G
AU  - Punwani,S
AU  - Moore,CM
AU  - Ahmed,HU
AU  - Emberton,M
AU  - ReIMAGINE,Study Group
DO  - 10.1371/journal.pone.0259672
PY  - 2022///
SN  - 1932-6203
TI  - The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses
T2  - PLoS One
UR  - http://dx.doi.org/10.1371/journal.pone.0259672
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35202397
UR  - http://hdl.handle.net/10044/1/95466
VL  - 17
ER  -
Download